Atlas Trials

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical trial NCT06052306 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06052306
Sponsor
Bayer
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Metastatic Castration-resistant Prostate Cancer
Start date
2023-09-20
Primary completion
2027-06-08
Enrollment
232

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.